This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Prasco® Launches Authorized Generic Of Shire's Carbatrol®





CINCINNATI, Jan. 12, 2012 /PRNewswire/ --  Prasco® Laboratories announced today it has entered into an agreement with Shire (NASDAQ: SHPGY) for the distribution in the U.S. of the Authorized Generic  version of Carbatrol® (Carbamazepine) Extended-Release Capsules in 100 mg, 200 mg and 300 mg strengths.

Carbamazepine Extended-Release Capsules are AB-rated, therapeutically equivalent and substitutable for the brand Carbatrol®. The product will be distributed in the U.S. under the Prasco label. Financial terms of the agreement were not disclosed.

"We are pleased to provide Carbamazepine Extended-Release Capsules to pharmacists and consumers," said Prasco chief executive officer Christopher H. Arington. "As a Prasco Authorized Generic, Carbamazepine Extended-Release Capsules will provide patients with a therapeutically equivalent product to the brand."

Indications

Carbatrol is a medicine used to treat:

  • certain types of seizures (partial, tonic-clonic, mixed).
  • certain types of nerve pain (trigeminal and glossopharyngeal neuralgia).

Carbatrol is not a regular pain medicine and should not be used for aches or pains.

Important Safety Information

Do not stop taking Carbatrol without first talking to your doctor. Stopping Carbatrol suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

W A RNING

SE RIOUS SKIN REACTIONS

Carbatrol may cause rare but serious rashes that may lead to death. These serious skin reactions are more likely to happen within the first four months of Carbatrol treatment but may occur at later times. These reactions can happen in anyone, but are more likely in people of Asian descent. If you are of Asian descent you may need a genetic blood test before you take Carbatrol to see if you are at a higher risk for serious skin reactions with this medicine.  Symptoms may include:

  • sk in rash
  • hives
  • s ores in your mouth
  • blistering or peeling of the skin

SE RIOUS BLOOD PROBLEMS

Carbatrol may cause rare but serious blood problems.  Symptoms may include:

  • f e v e r, sore throat or other infections that come and go or do not go away
  • eas y bruising
  • red or purple spots on your body
  • bleeding gums or nose bleeds
  • se v e re fatigue or weakness

Carbamazepine extended-release capsules, 100 mg, 200 mg and 300 mg, represent the latest product from Prasco in its expanding Authorized Generics portfolio. Carbatrol is registered in the United States Patent and Trademark Office. For additional important information, click   here to see the Full Prescribing Information, INCLUDING BOXED WARNING, or visit   www.prasco.com.

A b ou t Prasco Laboratories – Prasco, the Authorized Generics company, is a privately-held pharmaceutical company located in Mason, Ohio that specializes in Authorized Generics. Prasco authorized Generics provide patients with the identical brand drug experience at a price that competes with generics. Prasco Authorized Generics also simplify interactions between pharmacists and consumers because they are identical to branded drugs. Moreover, Prasco Authorized Generics offer brand pharmaceutical companies a strategic lifecycle management solution. For more information, visit   www.prasco.com.

A b ou t Carbatrol

Indications

Carbatrol is a medicine used to treat:

  • certain types of seizures (partial, tonic-clonic, mixed).
  • certain types of nerve pain (trigeminal and glossopharyngeal neuralgia).

Carbatrol is not a regular pain medicine and should not be used for aches or pains.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,120.89 -51.79 -0.30%
S&P 500 1,989.57 -4.72 -0.24%
NASDAQ 4,526.5270 -1.1620 -0.03%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs